Mechelen, Belgium, August 12, 2005 – Galapagos NV (Euronext: GLPG) today announced its financial results for the first half of 2005.
Onno van de Stolpe, Galapagos’ CEO. “Moreover, the fact that Galapagos was able to complete these major deals while undergoing the process of an initial public offering on Euronext shows the perseverance of both our research and business development teams.”
Key Figures First Half 2005
( € million, except net loss per share)
|
|
June 30, 2005
|
% change
|
June 30, 2004
|
|
Revenue
|
x
|
x%
|
2,264
|
|
Loss from operations
|
x
|
x%
|
-3,012
|
|
Finance income
|
x
|
x%
|
24
|
|
Loss before taxes
|
x
|
x%
|
-2,989
|
|
Taxes
|
x
|
|
-6
|
|
Net loss for the period
|
x
|
x%
|
-2,994
|
|
Basic loss per share
|
x
|
x%
|
-0,50
|
|
|
|
|
|
|
Cash and cash equivalents
|
x
|
|
10,665
|
Operational Review
Galadeno
- Asthma program licensed to GlaxoSmithKline (GSK)
- Collaborations with Celera Genomics and Novartis
- Target discovery alliances with Cystic Fibrosis Foundation
Galapagos
- Established Asinex drug discovery collaboration in bone and joint diseases
- Progress in kinase drug discovery collaboration with Biofocus
About Galapagos
Galapagos is a publicly traded, genomics-based drug discovery company (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA) that has successfully discovered and validated novel targets in the bone and joint diseases – osteoarthritis, osteoporosis and rheumatoid arthritis, as well as in asthma and Alzheimer’s disease. Proprietary targets and compounds resulting from these programs are used for Galapagos’ internal drug discovery programs, combined with selected out-licensing and partnering of projects during development. Galadeno, Galapagos’ partnering unit, provides reagents and functional screens to leading pharmaceutical, biotech and nutraceutical companies for rapid identification and validation of novel drug targets. Galapagos currently employs 71 people, including 17 PhDs, and occupies facilities in Mechelen, Belgium, and Leiden, The Netherlands. Partners include Bayer, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Novartis, Vertex and Wyeth.
More information about Galapagos and Galadeno can be found at www.glpg.com.
Contact:
Onno van de Stolpe
CEO Galapagos
Phone: +31 62 909 8028
E-mail: onno@galapagos.be